
Europe Hemoglobinopathies Market Report and Forecast 2024-2032
Description
Europe Hemoglobinopathies Market Report and Forecast 2024-2032
Europe Hemoglobinopathies Market Report and Forecast 2024-2032
Europe Hemoglobinopathies Market Outlook
The global hemoglobinopathies market size was valued at USD 6.9 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of thalassemia and sickle cell anemia. The global market is expected to grow at a CAGR of 5.1% during the forecast period of 2024-2032, with the values likely to attain USD 15.9 billion by 2032.
Key Takeaways
- Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The increasing prevalence of hemoglobinopathies in European countries is poised to directly impact the market demand for effective and affordable treatment solutions in coming years.
- One of the major Europe hemoglobinopathies market trends is the surge in drug approvals of innovative treatment therapies by the health regulatory bodies. In December 2023 , the European Medicines Agency (EMA) approved the first gene therapy Casgevy (exagamglogene autotemcel) developed by Vertex Pharmaceuticals (Ireland) Limited to treat transfusion‑dependent beta thalassemia and severe sickle cell disease.
- The market is witnessing a rise in strategic partnerships among the key market players to expand their presence in the European market. In March 2023 , AddMedica and Abacus Medicine Pharma Services entered a partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) in the Western Europe region.
Hemoglobinopathies are a group of inherited blood disorders that affect the structure, function, or production of the hemoglobin molecule. The condition is usually resulted due to genetic mutations that damage or deform the red blood cells. Sickle cell anemia and thalassemia are considered the most common types of hemoglobinopathies. The disorder presents a significant health challenge in Europe. Several factors such as technological advancements in screening and diagnostic tools, rigorous research, and development efforts, and rising regulatory support are expected to drive the Europe hemoglobinopathies market growth.
The increasing prevalence of hemoglobinopathies in Europe is poised to directly impact the market demand for effective and affordable treatment solutions. Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The rising cases of the disease stimulate innovation in screening, diagnosis, and management strategies. Moreover, the heightened patient awareness coupled with the growing advocacy efforts for improved access to care and treatments for hemoglobinopathies is likely to bolster Europe hemoglobinopathies market demand in the forecast period.
The favorable regulatory environment in the region is expected to improve access to innovative therapies for the growing patient base as well as encourage investments from the key market players. In December 2023 , the European Medicines Agency (EMA) granted approval to the first gene therapy Casgevy (exagamglogene autotemcel) developed by Ireland based Vertex Pharmaceuticals Limited to treat transfusion‑dependent beta thalassemia and severe sickle cell disease in patients aged 12 or older. The medication employs CRISPR/Cas9 gene editing technology and has the potential to reduce the burden of frequent transfusions, thereby improving the patient’s quality of life and elevating Europe hemoglobinopathies market value.
A major market trend is the rise in strategic partnerships among the key market players to share expertise and resources and subsequently expand their presence in the European market. In March 2023 , AddMedica (Specialty Pharma Company in France) and Abacus Medicine Pharma Services (a pharmaceutical company in England) entered a strategic partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) for patients aged 2 years and above. It is to be applied in three countries of western Europe, including Belgium, the Netherlands, and Luxembourg. Siklos has the potential to prevent red blood cells from taking a sickle-celled shape and reduce the risk of vaso-occlusive crises (VOCs) in the affected people. The increased emphasis on marketing and distribution of sickle cell therapies to ensure the accessibility of treatment options in the region is anticipated to augment the market share in the forecast period.
Europe Hemoglobinopathies Market Segmentation
Market Breakup by Type
- Thalassemia
- Sickle Cell Disease
- Other Hb Variants Diseases
- Stem-Cell Transplantation
- Blood Transfusions
- Analgesics
- Antibiotics
- Ace Inhibitors
- Hydroxyurea
- Monoclonal Antibody Medication
- Others
- Routine Red Blood Cell (RBC) Count
- Genetic Testing
- Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
- Hemoglobin Isoelectric Focusing (Hb IEF)
- Hemoglobin electrophoresis (Hb ELP)
- Hemoglobin Solubility Test
- Hospitals and Clinics
- Diagnostics Laboratories
- Others
- United Kingdom
- Germany
- France
- Italy
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Pfizer Limited
- Merck KGaA
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Neusoft Corporation
- Emmaus UK
- Biogen
FAQs
- What is the Europe hemoglobinopathies market forecast outlook for 2024-2032?
- What are the major factors aiding the Europe hemoglobinopathies market demand?
- What are the major Europe hemoglobinopathies market trends?
- What is the market segmentation based on the type?
- What are the various treatments available in the market?
- What is the market breakup by test type?
- What are the major end users of the market?
- What is the market segmentation by countries?
- Who are the key players involved in the Europe hemoglobinopathies market?
Meta description
The Europe hemoglobinopathies market is poised for growth, driven by the expansion of the global market, which was valued at USD 6.9 billion in 2023 and is projected to grow at a CAGR of 9.7% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe Hemoglobinopathies Market Overview
- 3.1 Europe Hemoglobinopathies Market Historical Value (2017-2023)
- 3.2 Europe Hemoglobinopathies Market Forecast Value (2024-2032)
- 4 Europe Hemoglobinopathies Market Landscape*
- 4.1 Europe Hemoglobinopathies: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe Hemoglobinopathies: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Treatment
- 5 Europe Hemoglobinopathies Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe Hemoglobinopathies Market Segmentation (2017-2032)
- 6.1 Europe Hemoglobinopathies Market (2017-2032) by Type
- 6.1.1 Market Overview
- 6.1.2 Thalassemia
- 6.1.3 Sickle Cell Disease
- 6.1.4 Other Hb Variants Diseases
- 6.2 Europe Hemoglobinopathies Market (2017-2032) by Treatment
- 6.2.1 Market Overview
- 6.2.2 Stem-Cell Transplantation
- 6.2.3 Blood Transfusions
- 6.2.4 Analgesics
- 6.2.5 Antibiotics
- 6.2.6 Ace Inhibitors
- 6.2.7 Hydroxyurea
- 6.2.8 Monoclonal Antibody Medication
- 6.2.9 Others
- 6.3 Europe Hemoglobinopathies Market (2017-2032) by Test Type
- 6.3.1 Market Overview
- 6.3.2 Routine Red Blood Cell (RBC) Count
- 6.3.3 Genetic Testing
- 6.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
- 6.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
- 6.3.6 Hemoglobin electrophoresis (Hb ELP)
- 6.3.7 Hemoglobin Solubility Test
- 6.4 Europe Hemoglobinopathies Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals and Clinics
- 6.4.3 Diagnostics Laboratories
- 6.4.4 Others
- 6.5 Europe Hemoglobinopathies Market (2017-2032) by Country
- 6.5.1 Market Overview
- 6.5.2 United Kingdom
- 6.5.3 Germany
- 6.5.4 France
- 6.5.5 Italy
- 6.5.6 Others
- 7 United Kingdom Hemoglobinopathies Market (2017-2032)
- 7.1 United Kingdom Hemoglobinopathies Market (2017-2032) by Type
- 7.1.1 Market Overview
- 7.1.2 Thalassemia
- 7.1.3 Sickle Cell Disease
- 7.1.4 Other Hb Variants Diseases
- 7.2 United Kingdom Hemoglobinopathies Market (2017-2032) by Treatment
- 7.2.1 Market Overview
- 7.2.2 Stem-Cell Transplantation
- 7.2.3 Blood Transfusions
- 7.2.4 Analgesics
- 7.2.5 Antibiotics
- 7.2.6 Ace Inhibitors
- 7.2.7 Hydroxyurea
- 7.2.8 Monoclonal Antibody Medication
- 7.2.9 Others
- 7.3 United Kingdom Hemoglobinopathies Market (2017-2032) by Test Type
- 7.3.1 Market Overview
- 7.3.2 Routine Red Blood Cell (RBC) Count
- 7.3.3 Genetic Testing
- 7.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
- 7.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
- 7.3.6 Hemoglobin electrophoresis (Hb ELP)
- 7.3.7 Hemoglobin Solubility Test
- 7.4 United Kingdom Hemoglobinopathies Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Hospitals and Clinics
- 7.4.3 Diagnostics Laboratories
- 7.4.4 Others
- 8 Germany Hemoglobinopathies Market (2017-2032)
- 8.1 Germany Hemoglobinopathies Market (2017-2032) by Type
- 8.1.1 Market Overview
- 8.1.2 Thalassemia
- 8.1.3 Sickle Cell Disease
- 8.1.4 Other Hb Variants Diseases
- 8.2 Germany Hemoglobinopathies Market (2017-2032) by Treatment
- 8.2.1 Market Overview
- 8.2.2 Stem-Cell Transplantation
- 8.2.3 Blood Transfusions
- 8.2.4 Analgesics
- 8.2.5 Antibiotics
- 8.2.6 Ace Inhibitors
- 8.2.7 Hydroxyurea
- 8.2.8 Monoclonal Antibody Medication
- 8.2.9 Others
- 8.3 Germany Hemoglobinopathies Market (2017-2032) by Test Type
- 8.3.1 Market Overview
- 8.3.2 Routine Red Blood Cell (RBC) Count
- 8.3.3 Genetic Testing
- 8.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
- 8.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
- 8.3.6 Hemoglobin electrophoresis (Hb ELP)
- 8.3.7 Hemoglobin Solubility Test
- 8.4 Germany Hemoglobinopathies Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospitals and Clinics
- 8.4.3 Diagnostics Laboratories
- 8.4.4 Others
- 9 France Hemoglobinopathies Market (2017-2032)
- 9.1 France Hemoglobinopathies Market (2017-2032) by Type
- 9.1.1 Market Overview
- 9.1.2 Thalassemia
- 9.1.3 Sickle Cell Disease
- 9.1.4 Other Hb Variants Diseases
- 9.2 France Hemoglobinopathies Market (2017-2032) by Treatment
- 9.2.1 Market Overview
- 9.2.2 Stem-Cell Transplantation
- 9.2.3 Blood Transfusions
- 9.2.4 Analgesics
- 9.2.5 Antibiotics
- 9.2.6 Ace Inhibitors
- 9.2.7 Hydroxyurea
- 9.2.8 Monoclonal Antibody Medication
- 9.2.9 Others
- 9.3 France Hemoglobinopathies Market (2017-2032) by Test Type
- 9.3.1 Market Overview
- 9.3.2 Routine Red Blood Cell (RBC) Count
- 9.3.3 Genetic Testing
- 9.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
- 9.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
- 9.3.6 Hemoglobin electrophoresis (Hb ELP)
- 9.3.7 Hemoglobin Solubility Test
- 9.4 France Hemoglobinopathies Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Hospitals and Clinics
- 9.4.3 Diagnostics Laboratories
- 9.4.4 Others
- 10 Italy Hemoglobinopathies Market (2017-2032)
- 10.1 Italy Hemoglobinopathies Market (2017-2032) by Type
- 10.1.1 Market Overview
- 10.1.2 Thalassemia
- 10.1.3 Sickle Cell Disease
- 10.1.4 Other Hb Variants Diseases
- 10.2 Italy Hemoglobinopathies Market (2017-2032) by Treatment
- 10.2.1 Market Overview
- 10.2.2 Stem-Cell Transplantation
- 10.2.3 Blood Transfusions
- 10.2.4 Analgesics
- 10.2.5 Antibiotics
- 10.2.6 Ace Inhibitors
- 10.2.7 Hydroxyurea
- 10.2.8 Monoclonal Antibody Medication
- 10.2.9 Others
- 10.3 Italy Hemoglobinopathies Market (2017-2032) by Test Type
- 10.3.1 Market Overview
- 10.3.2 Routine Red Blood Cell (RBC) Count
- 10.3.3 Genetic Testing
- 10.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
- 10.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
- 10.3.6 Hemoglobin electrophoresis (Hb ELP)
- 10.3.7 Hemoglobin Solubility Test
- 10.4 Italy Hemoglobinopathies Market (2017-2032) by End User
- 10.4.1 Market Overview
- 10.4.2 Hospitals and Clinics
- 10.4.3 Diagnostics Laboratories
- 10.4.4 Others
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication Year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by Year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share by Top 5 Companies
- 16.2 Bio-Rad Laboratories, Inc.
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 Bristol-Myers Squibb Company
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Novartis AG
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Pfizer Limited
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Merck KGaA
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Alnylam Pharmaceuticals, Inc.
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 Sanofi
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 Neusoft Corporation
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 Emmaus UK
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Biogen
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 17 Europe Hemoglobinopathies Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.